Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease
Identifieur interne : 000490 ( Istex/Corpus ); précédent : 000489; suivant : 000491Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease
Auteurs : Eng Tan ; Sin Cheah ; Stephanie Fook ; Kenneth Yew ; V Chandran ; Sau Lum ; Zhao YiSource :
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics [ 1552-4841 ] ; 2005-08-05.
English descriptors
- KwdEn :
Abstract
Pyridoxal‐5‐phosphate, the biological active form of pyridoxine, is a cofactor for dopa‐decarboxylase (DDC) enzyme. Pyridoxine may augment the conversion of levodopa to dopamine in the periphery and therefore decrease availability of levodopa to the brain. However, this effect can be negated in the presence of a DDC inhibitor, which potentiates plasma levodopa level. A single nucleotide polymorphism at the nucleotide 1947 in the catechol‐O‐methyltransferase (COMT) gene encodes the high (COMTH) and low activity (COMTL) forms of the enzyme. In this study, we examined the effect of the COMTL allele on the clinical response to pyridoxine in Parkinson's disease (PD) patients. PD patients who were on stable and optimized dose of levodopa were included in this study. Their mean motor and activities of living score improved after high dose pyridoxine (P = 0.09, P = 0.04), and worsened after a washout period (P = 0.005, P = 0.001). Using a multivariate model, the presence of the COMTL allele predicted response to pyridoxine, with the best outcome observed in COMTL/L homozygotes. Our observational study suggests that the status the functional COMTL variant may be potentially useful to select PD patients for high dose pyridoxine therapy. © 2005 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/ajmg.b.30198
Links to Exploration step
ISTEX:05E14E89420116ECC78DD79D2CBB27E47B4AD031Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease</title><author><name sortKey="Tan, Eng Ing" sort="Tan, Eng Ing" uniqKey="Tan E" first="Eng" last="Tan">Eng Tan</name><affiliation><mods:affiliation>Department of Neurology, Singapore General Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>National Neuroscience Institute, Singapore General Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>SingHealth Research, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Cheah, Sin Un" sort="Cheah, Sin Un" uniqKey="Cheah S" first="Sin" last="Cheah">Sin Cheah</name><affiliation><mods:affiliation>Department of Neurology, Singapore General Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacy, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Fook Hong, Stephanie" sort="Fook Hong, Stephanie" uniqKey="Fook Hong S" first="Stephanie" last="Fook">Stephanie Fook</name><affiliation><mods:affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Yew, Kenneth" sort="Yew, Kenneth" uniqKey="Yew K" first="Kenneth" last="Yew">Kenneth Yew</name><affiliation><mods:affiliation>Department of Neurology, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Chandran, V R" sort="Chandran, V R" uniqKey="Chandran V" first="V" last="Chandran">V Chandran</name><affiliation><mods:affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Lum, Sau Ing" sort="Lum, Sau Ing" uniqKey="Lum S" first="Sau" last="Lum">Sau Lum</name><affiliation><mods:affiliation>Department of Neurology, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Yi, Zhao" sort="Yi, Zhao" uniqKey="Yi Z" first="Zhao" last="Yi">Zhao Yi</name><affiliation><mods:affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:05E14E89420116ECC78DD79D2CBB27E47B4AD031</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/ajmg.b.30198</idno><idno type="url">https://api.istex.fr/document/05E14E89420116ECC78DD79D2CBB27E47B4AD031/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000490</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease</title><author><name sortKey="Tan, Eng Ing" sort="Tan, Eng Ing" uniqKey="Tan E" first="Eng" last="Tan">Eng Tan</name><affiliation><mods:affiliation>Department of Neurology, Singapore General Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>National Neuroscience Institute, Singapore General Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>SingHealth Research, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Cheah, Sin Un" sort="Cheah, Sin Un" uniqKey="Cheah S" first="Sin" last="Cheah">Sin Cheah</name><affiliation><mods:affiliation>Department of Neurology, Singapore General Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacy, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Fook Hong, Stephanie" sort="Fook Hong, Stephanie" uniqKey="Fook Hong S" first="Stephanie" last="Fook">Stephanie Fook</name><affiliation><mods:affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Yew, Kenneth" sort="Yew, Kenneth" uniqKey="Yew K" first="Kenneth" last="Yew">Kenneth Yew</name><affiliation><mods:affiliation>Department of Neurology, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Chandran, V R" sort="Chandran, V R" uniqKey="Chandran V" first="V" last="Chandran">V Chandran</name><affiliation><mods:affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Lum, Sau Ing" sort="Lum, Sau Ing" uniqKey="Lum S" first="Sau" last="Lum">Sau Lum</name><affiliation><mods:affiliation>Department of Neurology, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author><author><name sortKey="Yi, Zhao" sort="Yi, Zhao" uniqKey="Yi Z" first="Zhao" last="Yi">Zhao Yi</name><affiliation><mods:affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</title><title level="j" type="abbrev">Am. J. Med. Genet.</title><idno type="ISSN">1552-4841</idno><idno type="eISSN">1552-485X</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08-05">2005-08-05</date><biblScope unit="volume">137B</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="4">4</biblScope></imprint><idno type="ISSN">1552-4841</idno></series><idno type="istex">05E14E89420116ECC78DD79D2CBB27E47B4AD031</idno><idno type="DOI">10.1002/ajmg.b.30198</idno><idno type="ArticleID">AJMG30198</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1552-4841</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COMT variant</term><term>Parkinson's disease</term><term>pyridoxine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pyridoxal‐5‐phosphate, the biological active form of pyridoxine, is a cofactor for dopa‐decarboxylase (DDC) enzyme. Pyridoxine may augment the conversion of levodopa to dopamine in the periphery and therefore decrease availability of levodopa to the brain. However, this effect can be negated in the presence of a DDC inhibitor, which potentiates plasma levodopa level. A single nucleotide polymorphism at the nucleotide 1947 in the catechol‐O‐methyltransferase (COMT) gene encodes the high (COMTH) and low activity (COMTL) forms of the enzyme. In this study, we examined the effect of the COMTL allele on the clinical response to pyridoxine in Parkinson's disease (PD) patients. PD patients who were on stable and optimized dose of levodopa were included in this study. Their mean motor and activities of living score improved after high dose pyridoxine (P = 0.09, P = 0.04), and worsened after a washout period (P = 0.005, P = 0.001). Using a multivariate model, the presence of the COMTL allele predicted response to pyridoxine, with the best outcome observed in COMTL/L homozygotes. Our observational study suggests that the status the functional COMTL variant may be potentially useful to select PD patients for high dose pyridoxine therapy. © 2005 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Eng‐King Tan</name><affiliations><json:string>Department of Neurology, Singapore General Hospital, Singapore</json:string><json:string>National Neuroscience Institute, Singapore General Hospital, Singapore</json:string><json:string>SingHealth Research, Singapore General Hospital, Singapore</json:string></affiliations></json:item><json:item><name>Sin‐Yun Cheah</name><affiliations><json:string>Department of Neurology, Singapore General Hospital, Singapore</json:string><json:string>Department of Pharmacy, Singapore General Hospital, Singapore</json:string></affiliations></json:item><json:item><name>Stephanie Fook‐Chong</name><affiliations><json:string>Department of Clinical Research, Singapore General Hospital, Singapore</json:string></affiliations></json:item><json:item><name>Kenneth Yew</name><affiliations><json:string>Department of Neurology, Singapore General Hospital, Singapore</json:string></affiliations></json:item><json:item><name>V.R. Chandran</name><affiliations><json:string>Department of Clinical Research, Singapore General Hospital, Singapore</json:string></affiliations></json:item><json:item><name>Sau‐Ying Lum</name><affiliations><json:string>Department of Neurology, Singapore General Hospital, Singapore</json:string></affiliations></json:item><json:item><name>Zhao Yi</name><affiliations><json:string>Department of Clinical Research, Singapore General Hospital, Singapore</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pyridoxine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>COMT variant</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Pyridoxal‐5‐phosphate, the biological active form of pyridoxine, is a cofactor for dopa‐decarboxylase (DDC) enzyme. Pyridoxine may augment the conversion of levodopa to dopamine in the periphery and therefore decrease availability of levodopa to the brain. However, this effect can be negated in the presence of a DDC inhibitor, which potentiates plasma levodopa level. A single nucleotide polymorphism at the nucleotide 1947 in the catechol‐O‐methyltransferase (COMT) gene encodes the high (COMTH) and low activity (COMTL) forms of the enzyme. In this study, we examined the effect of the COMTL allele on the clinical response to pyridoxine in Parkinson's disease (PD) patients. PD patients who were on stable and optimized dose of levodopa were included in this study. Their mean motor and activities of living score improved after high dose pyridoxine (P = 0.09, P = 0.04), and worsened after a washout period (P = 0.005, P = 0.001). Using a multivariate model, the presence of the COMTL allele predicted response to pyridoxine, with the best outcome observed in COMTL/L homozygotes. Our observational study suggests that the status the functional COMTL variant may be potentially useful to select PD patients for high dose pyridoxine therapy. © 2005 Wiley‐Liss, Inc.</abstract><qualityIndicators><score>4.697</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1270</abstractCharCount><pdfWordCount>2429</pdfWordCount><pdfCharCount>15556</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>189</abstractWordCount></qualityIndicators><title>Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease</title><genre><json:string>brief communication</json:string></genre><host><volume>137B</volume><pages><total>4</total><last>4</last><first>1</first></pages><issn><json:string>1552-4841</json:string></issn><issue>1</issue><subject><json:item><value>Brief Research Communication</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1552-485X</json:string></eissn><title>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</title><doi><json:string>10.1002/(ISSN)1552-485X</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/ajmg.b.30198</json:string></doi><id>05E14E89420116ECC78DD79D2CBB27E47B4AD031</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/05E14E89420116ECC78DD79D2CBB27E47B4AD031/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/05E14E89420116ECC78DD79D2CBB27E47B4AD031/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/05E14E89420116ECC78DD79D2CBB27E47B4AD031/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2005</date></publicationStmt><notesStmt><note>National Medical Research Council</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease</title><author><persName><forename type="first">Eng‐King</forename><surname>Tan</surname></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Singapore General Hospital, Outram Road, Singapore 169608.</p></note><affiliation>Department of Neurology, Singapore General Hospital, Singapore</affiliation><affiliation>National Neuroscience Institute, Singapore General Hospital, Singapore</affiliation><affiliation>SingHealth Research, Singapore General Hospital, Singapore</affiliation></author><author><persName><forename type="first">Sin‐Yun</forename><surname>Cheah</surname></persName><affiliation>Department of Neurology, Singapore General Hospital, Singapore</affiliation><affiliation>Department of Pharmacy, Singapore General Hospital, Singapore</affiliation></author><author><persName><forename type="first">Stephanie</forename><surname>Fook‐Chong</surname></persName><affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</affiliation></author><author><persName><forename type="first">Kenneth</forename><surname>Yew</surname></persName><affiliation>Department of Neurology, Singapore General Hospital, Singapore</affiliation></author><author><persName><forename type="first">V.R.</forename><surname>Chandran</surname></persName><affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</affiliation></author><author><persName><forename type="first">Sau‐Ying</forename><surname>Lum</surname></persName><affiliation>Department of Neurology, Singapore General Hospital, Singapore</affiliation></author><author><persName><forename type="first">Zhao</forename><surname>Yi</surname></persName><affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</affiliation></author></analytic><monogr><title level="j">American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</title><title level="j" type="abbrev">Am. J. Med. Genet.</title><idno type="pISSN">1552-4841</idno><idno type="eISSN">1552-485X</idno><idno type="DOI">10.1002/(ISSN)1552-485X</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08-05"></date><biblScope unit="volume">137B</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="4">4</biblScope></imprint></monogr><idno type="istex">05E14E89420116ECC78DD79D2CBB27E47B4AD031</idno><idno type="DOI">10.1002/ajmg.b.30198</idno><idno type="ArticleID">AJMG30198</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Pyridoxal‐5‐phosphate, the biological active form of pyridoxine, is a cofactor for dopa‐decarboxylase (DDC) enzyme. Pyridoxine may augment the conversion of levodopa to dopamine in the periphery and therefore decrease availability of levodopa to the brain. However, this effect can be negated in the presence of a DDC inhibitor, which potentiates plasma levodopa level. A single nucleotide polymorphism at the nucleotide 1947 in the catechol‐O‐methyltransferase (COMT) gene encodes the high (COMTH) and low activity (COMTL) forms of the enzyme. In this study, we examined the effect of the COMTL allele on the clinical response to pyridoxine in Parkinson's disease (PD) patients. PD patients who were on stable and optimized dose of levodopa were included in this study. Their mean motor and activities of living score improved after high dose pyridoxine (P = 0.09, P = 0.04), and worsened after a washout period (P = 0.005, P = 0.001). Using a multivariate model, the presence of the COMTL allele predicted response to pyridoxine, with the best outcome observed in COMTL/L homozygotes. Our observational study suggests that the status the functional COMTL variant may be potentially useful to select PD patients for high dose pyridoxine therapy. © 2005 Wiley‐Liss, Inc.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>pyridoxine</term></item><item><term>COMT variant</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Research Communication</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-11-20">Received</change><change when="2005-03-22">Registration</change><change when="2005-08-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/05E14E89420116ECC78DD79D2CBB27E47B4AD031/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1552-485X</doi><issn type="print">1552-4841</issn><issn type="electronic">1552-485X</issn><idGroup><id type="product" value="AJMG"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="AMERICAN JOURNAL OF MEDICAL GENETICS PART B: NEUROPSYCHIATRIC GENETICS">American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</title><title type="short">Am. J. Med. Genet.</title></titleGroup><selfCitationGroup><citation type="ancestor" xml:id="cit1"><journalTitle>American Journal of Medical Genetics</journalTitle><accessionId ref="info:x-wiley/issn/01487299">0148-7299</accessionId><accessionId ref="info:x-wiley/issn/10968628">1096-8628</accessionId><pubYear year="2004">2004</pubYear></citation></selfCitationGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/ajmg.b.v137b:1</doi><numberingGroup><numbering type="journalVolume" number="137">137B</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2005-08-05">5 August 2005</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="1" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ajmg.b.30198</doi><idGroup><id type="unit" value="AJMG30198"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Research Communication</title><title type="tocHeading1">Brief Research Communications</title></titleGroup><copyright ownership="publisher">Copyright © 2005 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptReceived" date="2004-11-20"></event><event type="manuscriptAccepted" date="2005-03-22"></event><event type="firstOnline" date="2005-06-17"></event><event type="publishedOnlineFinalForm" date="2005-07-21"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2005-06-17"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">1</numbering><numbering type="pageLast">4</numbering></numberingGroup><correspondenceTo>Department of Neurology, Singapore General Hospital, Outram Road, Singapore 169608.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:AJMG.AJMG30198.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="15"></count><count type="wordTotal" number="2916"></count></countGroup><titleGroup><title type="main" xml:lang="en">Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease</title><title type="short" xml:lang="en">High Dose Pyridoxine in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af4 #af5" corresponding="yes"><personName><givenNames>Eng‐King</givenNames><familyName>Tan</familyName></personName><contactDetails><email>gnrtek@sgh.com.sg</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Sin‐Yun</givenNames><familyName>Cheah</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Stephanie</givenNames><familyName>Fook‐Chong</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kenneth</givenNames><familyName>Yew</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>V.R.</givenNames><familyName>Chandran</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Sau‐Ying</givenNames><familyName>Lum</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Zhao</givenNames><familyName>Yi</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="SG" type="organization"><unparsedAffiliation>Department of Neurology, Singapore General Hospital, Singapore</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="SG" type="organization"><unparsedAffiliation>Department of Pharmacy, Singapore General Hospital, Singapore</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="SG" type="organization"><unparsedAffiliation>Department of Clinical Research, Singapore General Hospital, Singapore</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="SG" type="organization"><unparsedAffiliation>National Neuroscience Institute, Singapore General Hospital, Singapore</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="SG" type="organization"><unparsedAffiliation>SingHealth Research, Singapore General Hospital, Singapore</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">pyridoxine</keyword><keyword xml:id="kwd3">COMT variant</keyword></keywordGroup><fundingInfo><fundingAgency>National Medical Research Council</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Pyridoxal‐5‐phosphate, the biological active form of pyridoxine, is a cofactor for dopa‐decarboxylase (DDC) enzyme. Pyridoxine may augment the conversion of levodopa to dopamine in the periphery and therefore decrease availability of levodopa to the brain. However, this effect can be negated in the presence of a DDC inhibitor, which potentiates plasma levodopa level. A single nucleotide polymorphism at the nucleotide 1947 in the catechol‐<i>O</i>‐methyltransferase (<i>COMT</i>) gene encodes the high (COMT<sup>H</sup>) and low activity (COMT<sup>L</sup>) forms of the enzyme. In this study, we examined the effect of the COMT<sup>L</sup> allele on the clinical response to pyridoxine in Parkinson's disease (PD) patients. PD patients who were on stable and optimized dose of levodopa were included in this study. Their mean motor and activities of living score improved after high dose pyridoxine (<i>P</i> = 0.09, <i>P</i> = 0.04), and worsened after a washout period (<i>P</i> = 0.005, <i>P</i> = 0.001). Using a multivariate model, the presence of the COMT<sup>L</sup> allele predicted response to pyridoxine, with the best outcome observed in COMT<sup>L/L</sup> homozygotes. Our observational study suggests that the status the functional COMT<sup>L</sup> variant may be potentially useful to select PD patients for high dose pyridoxine therapy. © 2005 Wiley‐Liss, Inc.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>High Dose Pyridoxine in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Eng‐King</namePart><namePart type="family">Tan</namePart><affiliation>Department of Neurology, Singapore General Hospital, Singapore</affiliation><affiliation>National Neuroscience Institute, Singapore General Hospital, Singapore</affiliation><affiliation>SingHealth Research, Singapore General Hospital, Singapore</affiliation><description>Correspondence: Department of Neurology, Singapore General Hospital, Outram Road, Singapore 169608.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sin‐Yun</namePart><namePart type="family">Cheah</namePart><affiliation>Department of Neurology, Singapore General Hospital, Singapore</affiliation><affiliation>Department of Pharmacy, Singapore General Hospital, Singapore</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephanie</namePart><namePart type="family">Fook‐Chong</namePart><affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kenneth</namePart><namePart type="family">Yew</namePart><affiliation>Department of Neurology, Singapore General Hospital, Singapore</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.R.</namePart><namePart type="family">Chandran</namePart><affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sau‐Ying</namePart><namePart type="family">Lum</namePart><affiliation>Department of Neurology, Singapore General Hospital, Singapore</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Zhao</namePart><namePart type="family">Yi</namePart><affiliation>Department of Clinical Research, Singapore General Hospital, Singapore</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief communication">shortCommunication</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-08-05</dateIssued><dateCaptured encoding="w3cdtf">2004-11-20</dateCaptured><dateValid encoding="w3cdtf">2005-03-22</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">15</extent><extent unit="words">2916</extent></physicalDescription><abstract lang="en">Pyridoxal‐5‐phosphate, the biological active form of pyridoxine, is a cofactor for dopa‐decarboxylase (DDC) enzyme. Pyridoxine may augment the conversion of levodopa to dopamine in the periphery and therefore decrease availability of levodopa to the brain. However, this effect can be negated in the presence of a DDC inhibitor, which potentiates plasma levodopa level. A single nucleotide polymorphism at the nucleotide 1947 in the catechol‐O‐methyltransferase (COMT) gene encodes the high (COMTH) and low activity (COMTL) forms of the enzyme. In this study, we examined the effect of the COMTL allele on the clinical response to pyridoxine in Parkinson's disease (PD) patients. PD patients who were on stable and optimized dose of levodopa were included in this study. Their mean motor and activities of living score improved after high dose pyridoxine (P = 0.09, P = 0.04), and worsened after a washout period (P = 0.005, P = 0.001). Using a multivariate model, the presence of the COMTL allele predicted response to pyridoxine, with the best outcome observed in COMTL/L homozygotes. Our observational study suggests that the status the functional COMTL variant may be potentially useful to select PD patients for high dose pyridoxine therapy. © 2005 Wiley‐Liss, Inc.</abstract><note type="funding">National Medical Research Council</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>pyridoxine</topic><topic>COMT variant</topic></subject><relatedItem type="host"><titleInfo><title>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</title></titleInfo><titleInfo type="abbreviated"><title>Am. J. Med. Genet.</title></titleInfo><subject><genre>article category</genre><topic>Brief Research Communication</topic></subject><identifier type="ISSN">1552-4841</identifier><identifier type="eISSN">1552-485X</identifier><identifier type="DOI">10.1002/(ISSN)1552-485X</identifier><identifier type="PublisherID">AJMG</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>137B</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>1</start><end>4</end><total>4</total></extent></part></relatedItem><relatedItem type="preceding"><titleInfo><title>American Journal of Medical Genetics</title></titleInfo><identifier type="ISSN">0148-7299</identifier><identifier type="ISSN">1096-8628</identifier><part><date point="end">2004</date></part></relatedItem><identifier type="istex">05E14E89420116ECC78DD79D2CBB27E47B4AD031</identifier><identifier type="DOI">10.1002/ajmg.b.30198</identifier><identifier type="ArticleID">AJMG30198</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000490 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000490 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:05E14E89420116ECC78DD79D2CBB27E47B4AD031
|texte= Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.19. |  |